Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2022 08:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
November 02, 2022 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments

– Initiated Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) and Phase 2 PAVIA clinical trial for non-proliferative diabetic retinopathy (NPDR) – – Presented positive...
October 26, 2022 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022

WATERTOWN, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
October 17, 2022 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...
September 29, 2022 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy

WATERTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
September 16, 2022 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...
September 06, 2022 16:01 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
August 03, 2022 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Developments

– First patient dosed in the Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) – – Presented positive twelve-month safety and efficacy data from Phase 1 DAVIO clinical...
August 02, 2022 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
July 27, 2022 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022

WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...